Copper(I) targeting in the Alzheimer's disease context: a first example using the biocompatible PTA ligand

Copper(I) coordinating ligands in the Alzheimer's disease context have remained unexplored, despite the biological relevance of this redox state of the copper ion. Here, we show that the PTA ligand can remove copper from Aβ, prevent reactive oxygen species production and oligomer formation, two...

Full description

Saved in:
Bibliographic Details
Published in:Metallomics 2015-08, Vol.7 (8), p.1229-1232
Main Authors: Atrián-Blasco, E, Cerrada, E, Conte-Daban, A, Testemale, D, Faller, P, Laguna, M, Hureau, C
Format: Article
Language:English
Subjects:
Adamantane - analogs & derivatives
Adamantane - pharmacology
Alzheimer Disease - drug therapy
Alzheimer Disease - metabolism
Amyloid beta-Peptides - chemistry
Amyloid beta-Peptides - metabolism
Copper - isolation & purification
Copper - metabolism
Humans
Life Sciences
Organophosphorus Compounds - pharmacology
Oxidation-Reduction
Reactive Oxygen Species - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Copper(I) coordinating ligands in the Alzheimer's disease context have remained unexplored, despite the biological relevance of this redox state of the copper ion. Here, we show that the PTA ligand can remove copper from Aβ, prevent reactive oxygen species production and oligomer formation, two deleterious events in the disease's etiology.
ISSN:1756-5901
1756-591X
DOI:10.1039/c5mt00077g